Synthesis and characterization and anti-plasmodial activity of Indolo[3,2-c] quinolone derivatives

Abstract

The ultimate goal of modern drug discovery is to identify a therapeutic agent that is effective against a disease. According to a recent study, there is a broad trend in drug research for novel medicines that includes molecular design of compound assemblies and modification of currently used physiologically active matrices. The Indolo[3,2-c] quinolone nucleus represents a noteworthy synthesis strategy for novel drug development. Many important effects, including anti-tubercular, anti-plasmodial, anti-inflammatory, antibacterial, analgesic, and anticancer activity, were revealed by indolo[3,2-c] quinolone derivatives. In retrospect, a number of novel medications and combinations have gradually gained approval for use, including mefloquine (1984), artemisinins (1994), artemether/lumefantrine (1999), atovaquone/proguanil (1999), and chlorproguanil/dapsone (2003). Nevertheless, each of these combinations has shown some limited utility. Thus, there is a pressing need to develop novel, practical, and effective antimalarial drugs.